Oxford Biomedica plc (OXB.L, OXBDF), on Wednesday, entered into a five-year licensing and option agreement with Viral Vector Manufacturing Facility, an Australian cell and gene therapy CDMO, to provide access to its viral vector platforms.
The agreement grants VVMF a worldwide, non-exclusive licence to the company's proprietary inAAVate platform, with an option to extend the licence to its LentiVector platform.
The licence forms part of a broader strategic collaboration to support VVMF in building viral vector manufacturing capabilities and accelerating its operational and commercial readiness.
The company will receive a low single-digit million licence fee and is eligible for future payments related to the use of its platforms.
The collaboration is expected to expand the company's global footprint, strengthen its presence in the Asia-Pacific region, and position Australia as a regional hub for cell and gene therapy manufacturing.
On Tuesday, OXB closed trading, 0.63% higher at GBp 637 on the London Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.